Viridian Therapeutics
VRDN
10 hedge funds and large institutions have $781K invested in Viridian Therapeutics in 2015 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 5 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
11% more funds holding
Funds holding: 9 → 10 (+1)
36% less capital invested
Capital invested by funds: $1.22M → $781K (-$440K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
+$533K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$102K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$70.6K |
| 4 |
ICAS
Investors Capital Advisory Services
Lynnfield,
Massachusetts
|
+$34.8K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$28.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$252K |
| 2 |
Barclays
London,
United Kingdom
|
-$126K |
| 3 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$67.4K |
| 4 |
SGH
Schonfeld Group Holdings
Jericho,
New York
|
-$24K |
| 5 |
FNYS
First New York Securities
New York
|
-$9.86K |
VRDN Hedge Fund Activity: Q3 2015 in Review
10 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q3 2015, worth a combined $781K — down 36% from $1.22M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new VRDN positions and 5 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.
The largest buyer was HighTower Advisors, opening a new position worth an estimated $533K. The largest seller was Heartland Advisors, exiting entirely with an estimated $252K sold.
- 10 institutional investors held Viridian Therapeutics (VRDN) as of Q3 2015, up from 9 in Q2 2015.
- Funds reported $781K of Viridian Therapeutics stock for Q3 2015, down 36% quarter-over-quarter.
- 6 funds opened new Viridian Therapeutics positions in Q3 2015 and 5 closed out, a net change of +1 holder.
- The largest Viridian Therapeutics buyer in Q3 2015 was HighTower Advisors, an estimated $533K added.
- The largest Viridian Therapeutics seller in Q3 2015 was Heartland Advisors, an estimated $252K sold.
Based on aggregated 13F filings for Q3 2015.